JAZZ PHARMACEUTICALS ($JAZZ) posted quarterly earnings results for Q4 2025 on Tuesday, February 24th. The company reported earnings of $6.64 per share, missing estimates of $6.65 by $0.01. The company also reported revenue of $1,197,930,000, beating estimates of $1,188,538,996 by $9,391,004.
Stock price change since market close: +3.46%
You can see Quiver Quantitative's $JAZZ stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
JAZZ PHARMACEUTICALS Insider Trading Activity
JAZZ PHARMACEUTICALS insiders have traded $JAZZ stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $JAZZ stock by insiders over the last 6 months:
- BRUCE C COZADD has made 0 purchases and 12 sales selling 107,000 shares for an estimated $18,565,125.
- PATRICIA CARR (SVP, Chief Accounting Officer) has made 0 purchases and 4 sales selling 9,979 shares for an estimated $1,766,185.
- ROBERT IANNONE (EVP, Global Head of R&D & CMO) sold 7,159 shares for an estimated $1,204,573
- RICK E WINNINGHAM sold 5,500 shares for an estimated $994,728
- HEATHER ANN MCSHARRY sold 3,415 shares for an estimated $607,126
- MARY ELIZABETH HENDERSON (SVP, Technical Operations) sold 2,238 shares for an estimated $379,365
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
JAZZ PHARMACEUTICALS Hedge Fund Activity
We have seen 292 institutional investors add shares of JAZZ PHARMACEUTICALS stock to their portfolio, and 287 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FRANKLIN RESOURCES INC added 1,129,995 shares (+164.0%) to their portfolio in Q4 2025, for an estimated $192,099,150
- MILLENNIUM MANAGEMENT LLC added 933,604 shares (+346.9%) to their portfolio in Q4 2025, for an estimated $158,712,680
- JPMORGAN CHASE & CO removed 822,517 shares (-44.1%) from their portfolio in Q4 2025, for an estimated $139,827,890
- BANK OF NEW YORK MELLON CORP added 715,361 shares (+160.2%) to their portfolio in Q4 2025, for an estimated $121,611,370
- CITADEL ADVISORS LLC removed 572,825 shares (-64.8%) from their portfolio in Q4 2025, for an estimated $97,380,250
- PACER ADVISORS, INC. removed 539,940 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $91,789,800
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 530,425 shares (-78.1%) from their portfolio in Q4 2025, for an estimated $90,172,250
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
JAZZ PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $JAZZ in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 01/12/2026
- Piper Sandler issued a "Overweight" rating on 12/10/2025
- Wells Fargo issued a "Overweight" rating on 11/18/2025
- B of A Securities issued a "Buy" rating on 11/18/2025
- Baird issued a "Outperform" rating on 11/18/2025
- Morgan Stanley issued a "Overweight" rating on 11/17/2025
- JP Morgan issued a "Overweight" rating on 10/27/2025
To track analyst ratings and price targets for JAZZ PHARMACEUTICALS, check out Quiver Quantitative's $JAZZ forecast page.
JAZZ PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $JAZZ recently. We have seen 11 analysts offer price targets for $JAZZ in the last 6 months, with a median target of $209.0.
Here are some recent targets:
- Ami Fadia from Needham set a target price of $235.0 on 01/12/2026
- Joon Lee from Truist Securities set a target price of $230.0 on 01/12/2026
- David Amsellem from Piper Sandler set a target price of $219.0 on 12/10/2025
- Ashwani Verma from UBS set a target price of $188.0 on 11/24/2025
- Jason Gerberry from B of A Securities set a target price of $247.0 on 11/18/2025
- Joel Beatty from Baird set a target price of $209.0 on 11/18/2025
- Mohit Bansal from Wells Fargo set a target price of $235.0 on 11/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
